Biotech stock Halozyme Therapeutics (HALO) is climbing back in constructive form from a severe drop in November. Shares got a boost after the drug-delivery developer reiterated its 2024 forecast and raised its 2025 outlook last month. Halozyme has developed a proprietary technology using an enzyme which helps deliver drugs and fluids under the skin via injection, named Enhanze. Drugmakers, including…
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。